Oncology Ventures is a New York-based seed-stage venture capital firm founded by Ben Freeberg, a cancer survivor and former Vice President at Optum Ventures. The firm closed its oversubscribed debut Fund I at $30 million in 2024, backed by prominent healthcare institutions including Cardinal Health, City of Hope, and Moffitt Cancer Center.
Beyond capital, it provides portfolio companies with operational guidance, strategic advice, and access to its extensive oncology network, including leading cancer centers and health systems.
Oncology Ventures targets technologies spanning the full cancer care continuum: early detection, precision diagnostics, patient navigation, care management, AI-powered treatment optimization, clinical trial enablement, and survivorship care. It does not invest in pharmaceutical or biotech drug development.
Recent and notable portfolio companies include RISA Labs, NexCure, CancerNavigator, Lumonus, Daymark Health, IgniteData, BIOMAKERS, WellBeam, Gabbi, mPATH, Reimagine Care, and FidoCure, among others. While specific check sizes are not publicly disclosed, investments have ranged from seed rounds to Series B stages.
People
- Ben Freeberg, Managing Partner
You last contacted this investor on .